CA2148823A1 - Sustained Release Microsphere Preparation Containing Antipsychotic Drug and Production Process Thereof - Google Patents

Sustained Release Microsphere Preparation Containing Antipsychotic Drug and Production Process Thereof

Info

Publication number
CA2148823A1
CA2148823A1 CA2148823A CA2148823A CA2148823A1 CA 2148823 A1 CA2148823 A1 CA 2148823A1 CA 2148823 A CA2148823 A CA 2148823A CA 2148823 A CA2148823 A CA 2148823A CA 2148823 A1 CA2148823 A1 CA 2148823A1
Authority
CA
Canada
Prior art keywords
sustained release
antipsychotic drug
microsphere preparation
release microsphere
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2148823A
Other languages
French (fr)
Other versions
CA2148823C (en
Inventor
Shigemi Kino
Tomonori Osajima
Hiroaki Mizuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Welfide Corp
Original Assignee
Welfide Corporation
Shigemi Kino
Tomonori Osajima
Hiroaki Mizuta
Yoshitomi Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18255017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2148823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Welfide Corporation, Shigemi Kino, Tomonori Osajima, Hiroaki Mizuta, Yoshitomi Pharmaceutical Industries Ltd. filed Critical Welfide Corporation
Publication of CA2148823A1 publication Critical patent/CA2148823A1/en
Application granted granted Critical
Publication of CA2148823C publication Critical patent/CA2148823C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

A sustained release microsphere preparation which is produced by including a hydrophobic antipsychotic drug such as bromperidol, haloperidol or the like into a base composed of a high molecular weight polymer having in vivo histocompatibility such as polylactic acid, poly(lactic-co-glycolic)acid or the like, and a process for the production thereof.
When a long-term administration is required, desired pharmacological effects can be obtained by one injection per 1 to 8 weeks, in stead of daily administration. As the result, considerable improvement in compliance at the time of maintenance therapy can be expected. Also, since a high molecular weight polymer having in vivo histocompatibility is used, surgical operations such as embedding and the like are not required at all, and subcutaneous and intramuscular administrations can be made easily absolutely in the same manner as the case of conventional suspension injections so that recovery of the material is not required. In addition, resistance and pain at the time of administration are small.
CA002148823A 1992-11-17 1993-11-15 Sustained release microsphere preparation containing antipsychotic drug and production process thereof Expired - Fee Related CA2148823C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33244192 1992-11-17
JP4-332441 1992-11-17

Publications (2)

Publication Number Publication Date
CA2148823A1 true CA2148823A1 (en) 1994-05-26
CA2148823C CA2148823C (en) 1999-03-09

Family

ID=18255017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002148823A Expired - Fee Related CA2148823C (en) 1992-11-17 1993-11-15 Sustained release microsphere preparation containing antipsychotic drug and production process thereof

Country Status (11)

Country Link
US (2) US5656299A (en)
EP (1) EP0669128B1 (en)
KR (1) KR100333115B1 (en)
AT (1) ATE188375T1 (en)
CA (1) CA2148823C (en)
DE (2) DE669128T1 (en)
DK (1) DK0669128T3 (en)
ES (1) ES2077547T3 (en)
GR (2) GR960300020T1 (en)
PT (1) PT669128E (en)
WO (1) WO1994010982A1 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP0998917A1 (en) * 1993-11-19 2000-05-10 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
PT729357E (en) * 1993-11-19 2005-06-30 Janssen Pharmaceutica Nv MICROENCAPSULATED 1,2-BWENZAZOLES
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
FR2748205A1 (en) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF INSOLUBLE ACTIVE SUBSTANCES
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
EP1210942B1 (en) * 1996-05-07 2007-03-21 Alkermes, Inc. Microparticles
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
CA2219698C (en) * 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6854841B1 (en) * 1998-04-17 2005-02-15 Elesys, Inc. Point-of-incidence ink-curing mechanisms for radial printing
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
GB9817078D0 (en) * 1998-08-05 1998-10-07 Habib Nagy A Device for liver surgery
PT1119359E (en) * 1998-09-30 2004-08-31 Lilly Co Eli FORMULATION OF 2-METHYL-TIENE-BENZODIAZEPINE
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
CA2369739C (en) * 1999-02-23 2008-12-16 Angiotech Pharmaceuticals, Inc. Compositions and methods for improving integrity of compromised body passageways and cavities
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
DK1341522T3 (en) * 2000-12-13 2006-02-13 Merckle Gmbh Microparticles with Enhanced Release Profile and Process for their Preparation
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
JP2004535431A (en) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド Zero-order long-term release coaxial implant
JP4490095B2 (en) 2001-06-29 2010-06-23 メドグラフト マイクロテック インコーポレイテッド Biodegradable injectable implants and related methods of manufacture and use
KR100521526B1 (en) 2001-07-10 2005-10-13 캐논 가부시끼가이샤 Particulate construct comprising polyhydroxyalkanoate and method for producing it
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
WO2003066021A2 (en) 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US6699963B2 (en) * 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
IL164152A0 (en) * 2002-03-26 2005-12-18 Teva Pharma Drug microparticles
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CN1694689A (en) * 2002-09-30 2005-11-09 阿库斯菲尔公司 Sustained release pharmaceutical formulation for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004073749A1 (en) * 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersant for sustained release preparations
JP2004331750A (en) 2003-05-02 2004-11-25 Canon Inc Magnetic structure comprising polyhydroxyalkanoate and method for producing the same and use thereof
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2007011955A2 (en) * 2005-07-18 2007-01-25 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) * 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
CA2565296C (en) * 2004-04-30 2014-06-03 Abraxis Bioscience, Inc. Sustained-release microspheres and methods of making and using same
ITMI20042232A1 (en) * 2004-11-19 2005-02-19 Unihart Corp PHARMACEUTICAL COMPOSITION CONTAINING CLOZAPINE
SI1838716T1 (en) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapine pamoate dihydrate
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7811604B1 (en) * 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
EP2089000A2 (en) * 2006-10-05 2009-08-19 Panacea Biotec Ltd. Injectable depot composition and its process of preparation
JP2010522196A (en) * 2007-03-22 2010-07-01 アルカームズ，インコーポレイテッド Coacervation process
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 The mixed suspension preparation of insulinotropic peptide and application thereof
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
BRPI0813274A2 (en) * 2007-06-25 2014-12-30 Otsuka Pharma Co Ltd MICROSPHERES HAVING CORE / COATING STRUCTURE
US9161943B2 (en) * 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2440283B1 (en) 2009-06-09 2018-08-01 Neuronano AB Microelectrode and multiple microelectrodes comprising means for releasing drugs into the tissue
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HUE046004T2 (en) 2011-04-25 2020-01-28 Shan Dong Luye Pharm Co Ltd Risperidone sustained release microsphere composition
CN103301461B (en) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 A kind of long acting injection and its preparation method and application
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EA033537B1 (en) 2013-03-11 2019-10-31 Durect Corp Injectable controlled release composition comprising high viscosity liquid carrier
KR101738127B1 (en) * 2014-08-08 2017-05-22 (주)비씨월드제약 A method for producing drug-containing sustained release micro particle
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (en) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
BR112022000413A2 (en) * 2019-07-12 2022-03-03 G2Gbio Inc Long-lasting formulation containing rivastigmine and method for preparing the same
CN111991397B (en) * 2020-10-13 2021-09-10 深圳善康医疗健康产业有限公司 Flupentixol melitracen microsphere and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
FR2534139B1 (en) * 1982-10-07 1986-08-29 Laruelle Claude NOVEL GALENIC FORM OF SULPIRIDE, METHOD FOR PREPARING SAME, AND MEDICINAL PRODUCT COMPRISING THIS NEW FORM
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS63122620A (en) * 1986-11-12 1988-05-26 Sanraku Inc Polylactic acid microsphere and production thereof
IT1216570B (en) * 1988-04-08 1990-03-08 Vectorpharma Int CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR THEIR PREPARATION.

Also Published As

Publication number Publication date
DE669128T1 (en) 1996-03-14
ES2077547T3 (en) 2000-06-16
DE69327542D1 (en) 2000-02-10
GR960300020T1 (en) 1996-03-31
EP0669128A4 (en) 1996-09-25
ES2077547T1 (en) 1995-12-01
US5656299A (en) 1997-08-12
GR3033016T3 (en) 2000-08-31
EP0669128A1 (en) 1995-08-30
WO1994010982A1 (en) 1994-05-26
US5871778A (en) 1999-02-16
KR950703936A (en) 1995-11-17
DE69327542T2 (en) 2000-07-06
EP0669128B1 (en) 2000-01-05
KR100333115B1 (en) 2002-12-02
CA2148823C (en) 1999-03-09
ATE188375T1 (en) 2000-01-15
PT669128E (en) 2000-06-30
DK0669128T3 (en) 2000-06-19

Similar Documents

Publication Publication Date Title
CA2148823A1 (en) Sustained Release Microsphere Preparation Containing Antipsychotic Drug and Production Process Thereof
Masters et al. Sustained local anesthetic release from bioerodible polymer matrices: a potential method for prolonged regional anesthesia
WO1997013502A3 (en) Prolonged release of gm-csf
DE3887616D1 (en) Implantable, biodegradable drug delivery system.
AU4275597A (en) Erythropoietin drug delivery system
AU7940487A (en) Sustained-release particulate preparation and process for preparing the same
CA2314151A1 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
MX9709699A (en) Composition for sustained release of non-aggregated erythropoietin.
GB2209937A (en) Water insoluble polypeptides
DE69930240D1 (en) MATRIZES MADE OF POLYMER AND HYDROPHOBIC COMPOUNDS FOR USE IN THE DISPOSAL OF MEDICINAL PRODUCTS
EP0301856A3 (en) Delivery system
AU2001276733A1 (en) Lactic acid polymer and process for producing the same
GEP20033078B (en) Controlled-Release Compositions of Betahistine
DE3889933D1 (en) Peroral drug preparation with delayed drug release.
CA2234585A1 (en) Prolonged release of gm-csf
Lim Development of Local Drug Delivery System: Prolonged Sciatic Nerve Blockade From Biodegradable Microspheres

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed